FDA Brief

Warning letters Drugs

FDA warning letter to

Empower Clinic Services, LLC dba Empower Pharmacy

MediumIssued Oct 15, 2021Posted Oct 26, 2021Office of Pharmaceutical Quality Operations, Division II

FDA warns Empower Pharmacy its compounded drugs missed outsourcing-facility conditions, including labeling and adverse-event reporting.

What happened

FDA inspected Empower Pharmacy in Houston, Texas, from February 12 to March 6, 2020, and issued a Form FDA 483 (inspection observations) on March 6, 2020. The investigator found that the firm’s compounded drug products did not meet section 503B conditions (the outsourcing-facility exemption from drug approval rules), including missing adverse-event reporting contacts on labels, incomplete semiannual drug reports, inadequate adverse-event procedures, wholesaling, and biological products without a biologics license.

What FDA found

  1. Some drug labels, including HCG, testosterone cypionate, FSH, and menotropins injectables, did not include the FDA MedWatch website and phone number for adverse-event reporting.

    Section 503B(a)(10) of the FDCA [21 U.S.C. §353b(a)(10)]
  2. The firm did not submit complete December 2019 and June 2020 reports listing all drugs compounded in the prior six months, including leuprolide acetate.

    Section 503B(b)(2) of the FDCA [21 U.S.C. §353b(b)(2)]
  3. The firm’s adverse-event reporting procedures did not require prompt investigation and a follow-up report for a serious unexpected adverse event within 15 calendar days of new information or as FDA requested.

    Section 503B(b)(5) of the FDCA [21 U.S.C. §353b(b)(5)]; 21 CFR 310.305(c)(2)
  4. The firm compounded a drug product that was sold by an entity other than the outsourcing facility that compounded it, which is prohibited wholesaling.

    Section 503B(a)(8) of the FDCA [21 U.S.C. §353b(a)(8)]
  5. The firm made Pyridoxine HCL 100mg/ml injection from bulk Pyridoxine, a component of an approved drug, making it essentially a copy of an approved drug without a documented clinical difference.

    Section 503B(a)(5), (d)(2)(B) of the FDCA [21 U.S.C. §353b(a)(5), (d)(2)(B)]
  6. The firm produced biological products without an approved biologics license application, and such products are not eligible for compounded-drug exemptions.

    Section 351(a)(1) of the Public Health Service Act

What FDA wants

Within 15 working days of receipt, notify FDA in writing on company letterhead of the specific steps taken to correct the violations, explain steps to prevent recurrence, and include supporting documentation; if unable to complete the matter, state the reason and timeframe.

Who should pay attention

  • outsourcing facilities and compounding pharmacies
  • clinics and prescribers buying compounded sterile injectables
  • companies relying on 503B adverse-event and drug-reporting compliance

This is a summary. Read the original letter on fda.gov.

Empower Clinic Services, LLC dba Empower Pharmacy's FDA history

  1. Empower Clinic Services, LLC dba Empower Pharmacy

    FDA warned Empower Pharmacy over unapproved compounded semaglutide/tirzepatide copies and sterile manufacturing deficiencies that put patients at risk.

    High risk
  2. Empower Clinic Services, LLC dba Empower Pharmacy

    FDA warns Empower Pharmacy that insanitary conditions in sterile drug compounding put patients at risk.

    High risk

Full company page

Similar letters to other companies

  1. Nanjing Hanxin Pharmaceutical Technology Co. Ltd.

    FDA warns Nanjing Hanxin of drug-ingredient quality failures and poor supplier oversight; its drugs face U.S. import detention.

    High risk
  2. Chongqing Qiancan Technology Co., Ltd.

    Chongqing Qiancan Technology, an API maker in China, refused FDA records requests; FDA placed its drugs on import alert 66-79.

    High risk
  3. Tianjin Healthcare Medical Technology Co., Ltd.

    Chinese API maker refused FDA records requests, and all its drugs now face a US import alert.

    High risk
  4. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low